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HIV and other bloodborne infectious agents, such as hepatitis B
or C, can be transmitted to health care workers during
occupational exposure. In all occupational exposure incidents
proper documentation is essential in order to claim compensation
at a later date. This article is limited to a brief overview of the
medical management of occupational exposure to HIV only.  
The risk of a health care worker acquiring HIV following
percutaneous occupational exposure is 0.3%.1 The risk following
mucous membrane exposure is 0.09%.1 Zidovudine post-
exposure reduces the risk of acquiring HIV by about 80%.2 The
current approach to post-exposure prophylaxis (PEP) is to stratify
the exposures by risk and to treat accordingly. In many instances
PEP is not indicated. 
When is PEP not indicated?
In instances where the risk of infection is extremely low or non-
existent, PEP is not indicated, as the risks of PEP will far
outweigh the benefits. PEP is not indicated when:
1. The material the health care worker was exposed to is not
infectious for HIV in the occupational setting,  e.g. vomitus,
urine, faeces or saliva (unless these are blood-stained).
2. The exposure was on intact skin.
3. The source patient is HIV-negative (unless there are clinical
features to suggest seroconversion illness, in which case PEP
should be commenced until further tests are done — consult with
a virologist or infectious diseases specialist).
4. The health care worker is HIV-positive.
High- versus low-risk exposures
The risk of acquiring HIV following occupational exposure is
determined by the nature of the exposure or by the infectiousness
of the source patient. High-risk exposures involve exposure to a
larger quantity of blood from the source patient. The following
are associated with an increased risk of HIV transmission1,2 and
are high-risk exposures:
1. Deep percutaneous sharps injuries.
2. Percutaneous exposure involving a hollow needle that was
used in a vein or an artery.
3. Visible blood on the sharp instrument involved in a
percutaneous injury.
4. The source patient has terminal AIDS. It is likely that
patients with a high viral load (e.g. ≥ 100 000 copies/ml) will also
be more infectious.
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PEP regimens
When PEP is indicated two regimens are recommended — a
basic two-drug regimen (zidovudine 300 mg plus lamivudine 150
mg, both given 12-hourly for 4 weeks) and an expanded three-
drug regimen (adding a protease inhibitor to the basic regimen)
for high-risk exposure. Guidelines for when to use the basic or
expanded regimens are given in Table I. The choice of protease
inhibitor should be based on cost and tolerability. The Centers for
Disease Control (CDC) recommend efavirenz as an alternative to
a protease inhibitor,1 but in my view the neuropsychiatric side-
effects of efavirenz are likely to be troublesome in PEP as
occupational HIV exposure is often a very stressful event.
Nevirapine should not be used in PEP as it has been associated
with severe hepatotoxicity in this setting.1 It is important to
realise that all current guidelines on PEP are empirical and not
based on evidence from randomised controlled trials — the only
evidence of efficacy is from a retrospective case control study
showing the benefit of zidovudine PEP.2
PEP is not well tolerated. Adverse events occur in about half
and therapy is discontinued in about one-third of patients1 — the
highest rates of adverse events occur with three-drug regimens.
Most of the adverse events are not life-threatening. Headache,
nausea and malaise are the commonest adverse events. 
Alternative antiretrovirals may be necessary because of
intolerance or resistance. For intolerance stavudine can be
substituted for zidovudine and efavirenz for a protease inhibitor
(lamivudine is generally well tolerated and substitution is rarely
necessary). In South Africa the proportion of HIV-infected
patients exposed to antiretroviral therapy is expanding
dramatically. Thus the chance of being exposed to drug-resistant
HIV will increase. If the source patient is receiving antiretroviral
therapy then assessment for potential resistance is important.
This should include a recent quantitative plasma HIV RNA test
(viral load) — if this is not suppressed then resistance is possible.
In cases where resistance is suspected, consultation with an
infectious diseases specialist or expert HIV treater is advised.
PEP should be commenced as soon as possible after the injury.
PEP was commenced within 4 hours of exposure in 89% of health
care workers in the only study showing the benefit of PEP.2
Animal data suggest that prophylaxis after 24 hours is ineffective.
However it is unknown whether humans benefit after delays
longer than 24 hours, so current national3 and CDC1
recommendations advise prophylaxis up to 7 days after
exposure, but the risks of prophylaxis in this setting are likely to
outweigh the benefits so this should be reserved for high- risk
cases. Beyond 7 days prophylaxis should generally not be
considered.
Monitoring after occupational exposure 
Following HIV exposure there is a need for psychosocial support
— this is beyond the scope of this article. Laboratory monitoring
is done to exclude acquisition of HIV infection and, for those
given PEP, to monitor toxicity. Health care workers should be
tested for HIV infection at the time of the exposure and again at 6
weeks, 3 months and 6 months after exposure. Full blood count
should be done at baseline and 2 weeks as zidovudine can cause
anaemia and neutropenia. The test of choice is the HIV antibody
test, which should be done in a laboratory (usually an enzyme
immunoassay or enzyme-linked immunosorbent assay (ELISA)
rather than with a clinic-based rapid test in order to ensure
adequate documentation. Health care workers should be
instructed to practice safer sex until their HIV test is negative 6
months following exposure. Nucleic acid amplification tests (e.g.
polymerase chain reaction or quantitative viral load) should not
be done serially to assess whether HIV was acquired as these
tests have a significant false-positive rate,4 which causes
unnecessary stress, and they are expensive. The only place for
such tests is in consultation with a virologist or infectious
diseases specialist when seroconversion illness is suspected. The
laboratory assessment of toxicity is limited to screening and
monitoring for the haematological toxicity of zidovudine — full
blood count should be performed at baseline, and after 2 and 4
weeks on antiretroviral therapy.
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Table I. Recommendations for post-exposure prophylaxis (PEP) after occupational exposure to infectious material (including blood,
cerebrospinal fluid, semen, vaginal secretions and synovial/pleural/ pericardial/peritoneal/amniotic fluid) from HIV-seropositive patients 
HIV status of source patient
Exposure Unknown Positive High risk*
Intact skin No PEP No PEP No PEP
Mucosal splash/non-intact skin Consider 2-drug regimen Recommend 2-drug regimen Recommend 2-drug regimen
Percutaneous (sharps) Recommend 2-drug regimen Recommend 2-drug regimen Recommend 3-drug regimen
Percutaneous (needle in vessel or Recommend 2-drug regimen Recommend 3-drug regimen Recommend 3-drug regimen
deep injury)
* Source patient has terminal AIDS or a high viral load.
